Cargando…

Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis

BACKGROUND: Efficacy of immune checkpoint inhibitors (ICIs) in metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma is inconsistent. Whether the efficacy of ICIs is comparable across different subgroups remains unknown. METHODS: We identified randomized controlled trials (RCTs) that com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kundel, Yulia, Sternschuss, Michal, Moore, Assaf, Perl, Gali, Brenner, Baruch, Goldvaser, Hadar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571828/ https://www.ncbi.nlm.nih.gov/pubmed/32869544 http://dx.doi.org/10.1002/cam4.3417

Ejemplares similares

Early PET‐CT in patients with pathological stage III colon cancer may improve their outcome: Results from a large retrospective study
por: Moore, Assaf, et al.
Publicado: (2018)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction
por: Bornschein, Jan, et al.
Publicado: (2019)

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity
por: Goldvaser, Hadar, et al.
Publicado: (2017)

Esophageal Cancer in Israel has Unique Clinico-Pathological Features: A Retrospective Study
por: Sarfaty, Michal, et al.
Publicado: (2017)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancer
por: Zlotnik, Oran, et al.
Publicado: (2021)

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
por: Goldstein, Daniel A., et al.
Publicado: (2020)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

Midesophageal Metastatic Disease After Treatment of Gastroesophageal Junction Adenocarcinoma
por: Brotherton, Tim, et al.
Publicado: (2022)

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
por: Wood, Anthony C, et al.
Publicado: (2022)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021)

Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
por: Babu, K. Govind, et al.
Publicado: (2019)

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
por: Reinhorn, Daniel, et al.
Publicado: (2021)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

Characterization of Biomarkers in Colorectal Cancer Liver Metastases as a Prognostic Tool
por: Michal, Sternschuss, et al.
Publicado: (2021)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
por: Mansoor, Wasat, et al.
Publicado: (2021)

Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma
por: Jiang, Di M., et al.
Publicado: (2020)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States †
por: Kim, Bradford J., et al.
Publicado: (2020)

Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
por: Okamoto, Takeshi, et al.
Publicado: (2022)

Mediastinal Lymph Node Dissection in Gastroesophageal Junction Adenocarcinoma
por: Kim, Jin-Jo
Publicado: (2023)

Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study
por: Zhang, Panpan, et al.
Publicado: (2018)

HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
por: Li, Weiling, et al.
Publicado: (2022)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Meningeal Carcinomatosis: A Metastasis from Gastroesophageal Junction Adenocarcinoma
por: Dam, Tanya, et al.
Publicado: (2013)

Incidence of Microscopically Positive Proximal Margins in Adenocarcinoma of the Gastroesophageal Junction
por: Gao, Fei, et al.
Publicado: (2014)

Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction
por: Clemons, Nicholas J, et al.
Publicado: (2013)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

ASO Author Reflections: Challenges in the Management of Gastroesophageal Junctional Adenocarcinoma
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Expression and Prognostic Value of RAD51 in Adenocarcinoma at the Gastroesophageal Junction
por: Redati, Darebai, et al.
Publicado: (2022)

Gastroesophageal junction adenocarcinoma 1-year after sleeve gastrectomy
por: Brown, Kevin C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_blaagdnjlfa0tr8930r1h3dlmq